Only in recent years has it been possible to identify a so-called Switch II pocket (SIIP) in the protein, which enables effective pharmacological inhibition.44 The majority of KRAS mutations in ductal pancreatic cancer are found in codons 12, 13, and 61, with the specific KRAS G12D, G12V, and G12R variants accounting for the majority (approx. 80%), while the therapeutically relevant G12C variant is only detected in approx. 2% of pancreatic cancers. Here, KRAS is linked to familial pancreatic carcinoma.